Product Information
LEVOCETIRIZINE 5 MG TABLET is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.0511 per EA under NDC 50228013690. Its NADAC has been published 380 times since Jun 26, 2019.
FDA first approved this application on Sep 9, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228013690
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOCETIRIZINE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203646FDA Approved
9/9/2014
TE Code
AB
On Market Since
9/9/2014
Pharmacological Classes
Price Statistics
The NADAC for LEVOCETIRIZINE 5 MG TABLET has been published 380 times since Jun 26, 2019, and over the history we have for it it has declined 47.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0511 per EA |
|---|---|
| All-time high | $0.0972 (Jul 10, 2019) |
| All-time low | $0.0511 (Sep 23, 2026) |
| 52-week high | $0.0568 |
| 52-week low | $0.0511 |
| Median price | $0.0732 |
| Average price | $0.0717 |
| Largest weekly change | -17.1% (Apr 17, 2024) |
| Weeks tracked | 380 |
| Tracking since | Jun 26, 2019 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levocetirizine dihydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOCETIRIZINE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOCETIRIZINE 5 MG TABLET, manufactured by ScieGen Pharmaceuticals, Inc., is $0.0511 per EA (NDC 50228013690), effective Sep 30, 2026.
How has the price of LEVOCETIRIZINE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOCETIRIZINE 5 MG TABLET has declined 47.4%. It has been tracked across 380 weekly CMS publications since Jun 26, 2019.
What are the highest and lowest recorded NADAC prices for LEVOCETIRIZINE 5 MG TABLET?
Since Jun 26, 2019, the NADAC for LEVOCETIRIZINE 5 MG TABLET has ranged from a low of $0.0511 (Sep 23, 2026) to a high of $0.0972 (Jul 10, 2019), with a median of $0.0732 per EA.
Are there cheaper alternatives to LEVOCETIRIZINE 5 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LEVOCETIRIZINE 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LEVOCETIRIZINE 5 MG TABLET?
LEVOCETIRIZINE 5 MG TABLET (NDC 50228013690) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.